Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment
{{output}}
The FDA approval of Otarmeni, an AAV-based gene therapy for biallelic OTOF-associated sensorineural hearing loss, represents a conceptual shift in otology: from bypassing defective auditory physiology to restoring it. Unlike cochlear implantation, which circum... ...
